ABSK043 plus Osimertinib for advanced EGFR-mutant NSCLC
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, ABSK043, combined with a targeted therapy called osimertinib for people with advanced or metastatic NSCLC that has an EGFR mutation and is PD-L1 positive. It aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lung cancer called non-small cell lung cancer (NSCLC), with adenocarcinoma as the main cell type.
- Your cancer is locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body).
- You have at least one tumor that can be measured on scans.
- You are in good overall health, with an ECOG score of 0 or 1 (meaning you can do most daily activities on your own).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new drug called SYS6010 combined with osimertinib for people with advanced non-small cell lung cancer that has specific EGFR mutations. It aims to see if this combination works better than current treatments.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
This study tests adding chemotherapy (pemetrexed and carboplatin) to the targeted drug osimertinib (Tagrisso) for people with a specific type of advanced lung cancer (EGFR-mutated adenocarcinoma) that is not controlled well by osimertinib alone. The goal is to see if the combination helps people live longer or better.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.